Agroaxis creates the first GreenMab® technology platform with plants Snuff “Human “Insulin for obtaining

The biotechnology company Agroaxis, located the Technology Park of Puerto e Santa María, Cádiz (Spain) founded in 2010,  is specialised in R&D, production and marketing of biotech drugs produced through GreenMab ® technology platform  and the  commercialization of nutraceutics products.

The innovative process of the platform allows to significantly reducing production costs while maintaining the highest standards of quality, resulting in a significant reduction of the final sales price.

The production structure of their technology Vertical Greenhouse Pharming ( VPG ® ) formed by vertical structures for crop production using a hydroponics system , integrated into tight spaces with low  energy requirements, for the production of recombinant proteins and monoclonal antibodies for obtaining of medications such as insulin , EPO, etc.

Parallel Agroaxis is leading a research project in collaboration with the University of Santiago de Compostela and the University of Cadiz, for the “production of a human protein therapeutic use vegetable biofactories “funded through the Sub INNPACTO 2011, financed European Funds, the Ministry of Economy and  Competitiveness.  The project is in its third year of implementation and aims to use snuff as biofactory plant for the production of EPO.

The young company has also received support from the Ministry of Science and Innovation through the Support for the recruitment of highly qualified through Subprograma Inncorpora 2010  and Inncorpora  FPGS, Inncorpora  TU 2011 through the Ministry of Economy and Competitiveness and the granting of  Innplanta 2011  for the  acquisition of sophisticated equipment for R & D.

For more information contact:

Head of Communication and Marketing: Paula Esteban del Rio
Mobile: +34 638 438 509

More on Agroaxis

The advances in molecular biology and more particularly recombinant DNA technology has allowed nutritionally valuable products, healthcare and industry , can be produced in large quantities at low cost and with increased biosafety.
The idea of using plant systems for the production of recombinant proteins has ceased to be a challenge to become a reality and alternative for the biopharmaceutical industry.

AGROAXIS decided to use and adapt the System NGS® to all their technology platforms to respond to the growing need of a new culture technologies and as a result of water scarcity and soil low yields increasingly overexploited.

More articles

  • Agroaxis hires three more technologists with the grant Inncorpora TU of the Ministry of Economy and Competitiveness
  • Agroaxis creates the first GreenMab® technology platform with plants Snuff “Human “Insulin for obtaining


    Copyright 2013 Agroaxis. All Rights Reserved
    Legal Advice